MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clbc.2020.05.006

Медицинская библиотека · Clinical breast cancer · 2020

Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer.

Franzese Ciro, Comito Tiziana, Viganò Luca, Pedicini Vittorio, Franceschini Davide, Clerici Elena, Loi Mauro, Donadon Matteo, Poretti Dario, Solbiati Luigi, Torzilli Guido, Scorsetti Marta

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

In the context of metastatic breast cancer, dissemination to the liver is a frequent occurrence. We aimed to evaluate the outcome and toxicity of metastatic breast cancer with liver oligometastases treated with metastases-directed therapies (MDTs), including surgery, stereotactic body radiation therapy, or thermal ablation (radiofrequency or microwaves).

PATIENTS AND

METHODS

We included patients with diagnosis of 1 to 5 liver metastases. Selection criteria included also age > 18 years; Eastern Cooperative Oncology Group performance status 0 to 2; absence of extra-hepatic disease or other controlled metastatic sites. Endpoints were liver progression-free survival (LPFS), progression-free survival (PFS), and overall survival.

RESULTS

A total of 72 patients were included. Previous local treatments were performed in 13 (18.1%) patients, whereas systemic therapy was used in 81.9% of cases. Treatment of choice was stereotactic body radiation therapy in 54 (75%) patients followed by surgery (13 patients; 18%) and thermal ablation (5 patients; 7%). With a median follow-up of 26.2 months, LPFS at 1 and 2 years was 52.4% and 38.8%, respectively. The number of metastases predicted LPFS (hazard ratio [HR], 1.70; P = .004). Rates of PFS were 38.7% and 22% at 1 and 2 years, respectively. Systemic therapy before MDT (HR, 2.89; P = .016) was correlated with PFS. Overall survival at 1 and 2 years was 95.5% and 76.9%, respectively. Human epidermal growth factor receptor 2 status correlated with survival (HR, 1.82; P = .010).

CONCLUSION

Combination of systemic therapy with liver MDT in oligometastatic breast cancer results in durable disease control in a significant proportion of patients. Tumor biology, prior treatment, and extent of disease may be useful to guide the decision to add MDT to standard therapy.

Для цитирования: Franzese Ciro, Comito Tiziana, Viganò Luca, Pedicini Vittorio, Franceschini Davide, Clerici Elena, Loi Mauro, Donadon Matteo, Poretti Dario, Solbiati Luigi, Torzilli Guido, Scorsetti Marta. Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer.. Clinical breast cancer. 2020. DOI: 10.1016/j.clbc.2020.05.006.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.